Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent's Analytical Services Laboratory in Research Triangle Park
Catalent Stock: Is CTLT Outperforming the Healthcare Sector?
Catalent Cut to Neutral at Baird as Analyst Unable to Find Valuation in a Deal Break
Catalent Cut to Neutral From Outperform by Baird
Catalent Analyst Ratings
Baird Downgrades Catalent(CTLT.US) to Hold Rating, Maintains Target Price $63.5
Hold Rating on Catalent Amid Deal Uncertainties and Conservative Financial Outlook
Sharp Sword! The FTC sues three major pharmaceutical 'middlemen', vowing to correct the distorted chain of interests.
①The USA FTC announced on its official website that it has filed a lawsuit against three major pharmaceutical benefit managers and their affiliated organizations, accusing them of engaging in anti-competitive and unfair rebate practices; ② The FTC also "explicitly stated" in the declaration that it is deeply concerned about the roles played by Eli Lilly, Novo-Nordisk, and Sanofi, insulin pharmaceutical companies, and may suggest in future enforcement actions to prosecute these pharmaceutical manufacturers.
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
Do Options Traders Know Something About Catalent (CTLT) Stock We Don't?
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
Catalent | 10-K: FY2024 Annual Report
Contract Development & Manufacturing Organization (CDMO) Market Insights & Forecast 2024-2028, Featuring Profiles of Catalent, Recipharm, Evotec, Lonza, Biomerieux and Thermo Fisher Scientific - ResearchAndMarkets.com
Express News | William Blair Reiterates Market Perform on Catalent
Catalent Delays 10-K Filing
Express News | Catalent Inc Says Files Non-Timely 10-K With U.S. SEC
Is Catalent (NYSE:CTLT) A Risky Investment?
American Injectables CEO Beau Garrett Comments on the Catalent-Novo Transaction: A Catalyst for Competition and Innovation
Catalent Ends FY24 on a Strong Note Ahead of Novo Buyout